Home > News > Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Lung Cancer
Read Time: 4 mins

Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

Published Online: November 30th 2015 European Oncology & Haematology, 2015;11(2):94–9 DOI: https://doi.org/10.17925/EOH.2015.11.02.94
Authors: Christian Rolfo, Ignacio Gil-Bazo, Solange Peters
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The development of oncogene-directed targeted therapies represents a new paradigm in the treatment of non-small cell lung cancer (NSCLC), offering improved outcomes compared with chemotherapy. Rearrangements of the anaplastic lymphoma kinase (ALK) gene are major oncogenic drivers in a subset of NSCLC patients. Since its launch in 2011, the ALK inhibitor crizotinib has become the standard of care in ALK-positive NSCLC, but resistance inevitably develops. Ceritinib and alectinib have received regulatory approval: the former in Europe, US and elsewhere in the world, the latter in Japan. ALK inhibitors target multiple pathways, and may therefore be associated with a wide range of adverse events (AEs), including gastrointestinal AEs, hepatotoxicity and, in the case of crizotinib and ceritinib, cardiac effects. While the majority of these AEs are reversible, manageable and not severe, it is important that both physician and patients are aware of toxicities to ensure prompt treatment. This article discusses the management of AEs in patients receiving currently approved ALK inhibitors, including treatment, regular monitoring, drug discontinuation or dose reduction and physician/patient education. Proactive management of AEs enhances patient quality of life and optimises the therapeutic index of these agents.

Keywords

Alectinib, ceritinib, crizotinib, ALK-positive non-small cell lung cancer

Article:

The development of targeted therapies has resulted in a new paradigm in the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and ALK tyrosine kinase inhibitors (TKIs) are the standard of care in ALK-positive NSCLC. However, ALK inhibitors also present new challenges. As a result of improved outcomes, patients will be receiving these agents for long periods of time. Furthermore, these drugs often target multiple pathways and may cause a range of toxicities. Since ALK inhibitors will be used by a multidisciplinary team in a specific subgroup of patients, physicians are likely to have limited experience in their use.sup>1 It is therefore essential that physicians and caregivers are aware of treatment-related adverse events (AEs) in order to optimise their management and thus enhance the patient’s quality of life. This article will focus on the management of AEs in ALK-positive NSCLC receiving targeted therapy.

The Role of ALK Signalling in NSCLC and the Use of Tyrosine Kinase Inhibitors
NSCLC is characterised by extensive genomic instability, which results in dramatic functional changes and is the molecular basis of lung carcinogenesis.2,3 Among the most frequently encountered targetable genetic alterations are chromosomal rearrangements of the ALK gene, which encodes a receptor tyrosine kinase. The ALK association with NSCLC was reported in 2007, following the discovery of a small inversion within chromosome 2p that juxtaposes the 5′ end of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the 3′ end of the ALK gene, resulting in the novel fusion oncogene EML4-ALK in NSCLC cells.4 ALK-rearranged tumours depend on ALK for growth and survival and are therefore sensitive to ALK inhibitors.4,5 ALK-positive NSCLC accounts for 4–5 % of adenocarcinomas of the lung,6 and is more common in males than in females.7 The majority of cases of ALK rearrangement arise in patients with no smoking history or light smokers.8,9

ALK inhibitors have shown dramatic and sustained responses in clinical studies. The first-in-class crizotinib (Xalkori®, Pfizer) is an oral, small-molecule TKI that targets ALK, MET and ROS1,10 and received accelerated approval from the US Food and Drug Administration (FDA) in 2011.11 Since its launch, crizotinib has become the standard of care in ALK-positive NSCLC. However, disease typically relapses


within a year because of the development of drug resistance.12,13 As a consequence, second-generation ALK inhibitors have been developed with increased potency and potential to overcome acquired resistance to crizotinib, notably being characterised by a broader activity encompassing several secondary mutated resistant ALK proteins, including ceritinib and alectinib. In 2014, ceritinib (Zykadia®, Novartis), an oral, small-molecule, ATP-competitive, TKI of ALK,14 received FDA Breakthrough Therapy designation for the second-line treatment of ALK-positive NSCLC following a clinical study of patients with metastatic ALK-positive NSCLC.15 Unlike crizotinib, ceritinib does not inhibit the kinase activity of MET, but inhibits the insulin-like growth factor 1 (IGF-1) receptor as well as ROS1 (see Figure 1).16 A novel ALK inhibitor, alectinib (Roche/Chugai), also selectively inhibits ALK with a high affinity, as well as RET.17 Alectinib (Alecensa®, Roche, Chugai) is approved in Japan and has received FDA Breakthrough Therapy designation. Another promising ALK inhibitor, AP26113 (Brigatinib®, Ariad), has also received Breakthrough Therapy designation by the FDA following the results of a phase I/II trial.18

Other second-generation ALK inhibitors are in early-stage clinical development, including X-396 (Xcovery);19 PF-06463922 (Pfizer),20 ASP302621 and TSR-011 (Tesaro).22

Clinical Trial Data Describing the Efficacy and Safety of ALK Inhibitors

In two phase III studies, crizotinib was found to be superior to first- and second-line standard chemotherapy in patients with previously treated, advanced ALK-positive NSCLC.23,24 The most common AEs associated with crizotinib include visual disorders, gastrointestinal effects (nausea, diarrhoea, vomiting, constipation), oedema and fatigue (see Table 1).11 Among 497 patients for whom data are listed in the prescribing information, deaths within 28 days of the last dose of study drug occurred in 45 patients. Ten (2.5 %) patients died within 28 days of their first dose of study drug. Causes of death included disease progression (32 patients), respiratory events (9) and other (4). Respiratory causes of death included pneumonia (2), hypoxia (2), acute respiratory distress syndrome (ARDS) (1), dyspnoea (1), pneumonitis (1), empyema (1) and pulmonary haemorrhage (1). Other causes of deaths included septic

shock, disseminated intravascular coagulopathy (DIC), cardiovascular event and death due to unknown cause (1 each).11 Rates of AEs were similar in the recent study, in which crizotinib was used in the first-line setting.24 Following prolonged treatment with crizotinib, new AEs have not emerged.25 The recommended dose of crizotinib is 250 mg orally, twice daily until disease progression or no longer tolerated by the patient. In patients with severe renal impairment (creatinine clearance <30 ml/ minute) not requiring dialysis, the dosage is 250 mg orally, once daily.



The safety evaluation of ceritinib is based on data from the ASCEND 1 (A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase) phase I study of ceritinib (n=255).26 Dose reductions due to AEs were


reported in 59 % of patients. The most frequent AEs, reported in at least 10 % of patients, which led to dose reductions or interruptions are listed in Table 1. Fatal adverse reactions occurred in 5 % of patients. These comprised: pneumonia (four patients), respiratory failure, interstitial lung disease (ILD)/pneumonitis, pneumothorax, gastric haemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade and sepsis (one patient each). Discontinuation of therapy due to AEs occurred in 10 % of patients. The most frequent AEs leading to discontinuation in 1 % or more of patients were pneumonia, ILD/ pneumonitis and decreased appetite.27

In a phase I/II trial, among patients who progressed on or were intolerant to crizotinib, alectinib achieved an overall response rate (ORR) of 55 %, including patients with central nervous system (CNS) metastases and good tolerability in crizotinib pre-treated NSCLC patients.17,28,29 Recent phase II clinical trial data (NP28673 study) show that alectinib may be effective in ALK-positive NSCLC patients who had progressed on crizotinib; most had also failed prior chemotherapy and had CNS metastases.30,31 Dose reductions due to AEs occurred in 8.7 % of patients, dose interruptions due to AEs occurred in 19.65 of patients and drug withdrawals due to AEs occurred in 8.0 % of patients.

The subsequent discussion will focus on managing AEs associated with crizotinib, ceritinib and alectinib (see Table 1) since, at the time of writing, these are the only three ALK inhibitors to have received regulatory approval.

Management of Adverse Events Associated with the Use of ALK Inhibitors

In clinical trials, crizotinib, ceritinib and alectinib were all relatively well tolerated. While the possibility of serious AEs from currently available

ALK inhibitors is relatively low, there is a need for regular monitoring to mitigate the risk. It is therefore essential to educate physicians on strategies to manage the AEs associated with these drugs.

Gastrointestinal Effects

Gastrointestinal effects are the most common AEs associated with crizotinib and ceritinib, and have also been reported in alectinib (see Table 1). Taking these agents with meals has been shown to reduce nausea in some patients.25 Anti-emetics such as metoclopramide or dimenhydrinate may be prescribed.32 Prochlorperazine and 5-HT3 receptor antagonists, such as ondansetron, should be avoided with crizotinib and ceritinib because of the risk of QT prolongation.32 Diarrhoea should be managed by dietary modification, hydration and, in severe cases, the use of a medication such as loperamide.32 Constipation should be managed using laxatives and dietary modification.32 In severe cases, dose modification may be considered.27 Dyseugia, including a heightened taste for sweet and sour but diminished taste for hot and spicy, has also been reported with crizotinib7,24 and alectinib;33 however, a recent report describes a case of crizotinib-induced dysgeusia that was resolved by switching to alectinib.34

Hepatotoxicity
Since crizotinib, ceritinib and alectinib are metabolised primarily in the liver, hepatic impairment can result in increased drug concentrations. These agents should be used with caution in patients with significant hepatic dysfunction. Abnormalities in liver enzymes have been reported in clinical trials of crizotinib, ceritinib and alectinib.11,17,27,35 Patients taking crizotinib, ceritinib and alectinib should be monitored with laboratory tests including alanine transaminase (ALT), aspartate aminotransferase (AST), γ-glutamyl transpeptidase and total bilirubin once a month and as clinically indicated, with more frequent testing in patients who develop elevations of liver enzymes (see Table 3), particularly during the first 2 months of treatment, when most elevations of liver enzymes are reported. Abnormal liver tests were reversible and reduced to baseline in the majority of patients with dose modification. Based on the results, dose modification, temporary or permanent drug discontinuation may be considered (see Table 4).11,27 In the case of impaired reduced hepatic function, patients should be advised to report any symptoms that may indicate hepatic injury: fatigue, jaundice, loss of appetite, dark urine, pruritus, nausea or vomiting, hypochondrial pain and bleeding or bruising more easily than normal.27,33

Cardiac Effects

Cardiac AEs, primarily bradycardia and QT elevation, have been reported with crizotinib and ceritinib but not with alectinib, though the number of treated patients with alectinib is small.11,27 It has been suggested that all patients should undergo cardiac evaluation before starting ALK-inhibitor therapy. This should include: heart rate, blood pressure, electrocardiography and electrolyte monitoring (specifically potassium, calcium and magnesium).32 These parameters should be monitored at intervals determined by the patient’s cardiovascular risk profile. Patients should be advised to report any new chest pain or discomfort, dizziness, lightheadedness, fainting or abnormal heartbeats.27 It is important to regularly update the list of patient’s concomitant medications. Concomitant use of ALK inhibitors and agents known to cause bradycardia (e.g. beta-blockers, non-dihydropyridine calcium channel blockers, clonidine and digoxin) or QT prolongation should be avoided.27,32 If co-administration cannot be avoided, dose reduction of ALK inhibitors may be considered. Crizotinib and ceritinib should be avoided in patients with congenital long QT syndrome. In cases of nonlife- threatening symptomatic bradycardia that is not life threatening, ALK inhibitors should be discontinued until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above, after which dose modification may be considered. Electrolyte abnormalities (specifically potassium, calcium and magnesium) should be corrected.27,3

Haematological Effects

Grade 3 or 4 lymphopenia, neutropenia and thrombocytopenia has been reported with crizotinib,11 and neutrophenia with alectinib (see Table 1).17 If a patient experiences grade 3 or 4 haematological toxicity, the ALK inhibitor should be discontinued until complete blood cell counts return to grade ≤2. According to the crizotinib prescribing information, in cases of grade 4 myelosuppression with crizotinib, the dose should be reduced to 200 mg twice daily when treatment is resumed. In the case of recurrent haematological toxicity, crizotinib should be withheld again until recovery to grade ≤2, then resumed at 250 mg once daily. Crizotinib should be permanently discontinued in the event of further grade 4 recurrence.11

Pulmonary Effects

In patients with unexpected lung symptoms, such as dyspnoea, fever, cough with or without mucous or chest pain, ILD and pneumonitis should be considered and ALK inhibitors discontinued.11,27,35 Due to the high incidence of pulmonary disease at baseline, it can be difficult to diagnose drug-associated pneumonitis and ILD. Chest computed tomography (CT) examination and, if indicated, pulmonary function test should be performed. Treatment should be discontinued if ILD or pneumonitis is confirmed. Preliminary data suggest that the addition of steroid medication enables retreatment with crizotinib, but further studies are required to confirm this.37 At the time of writing, no data were available for other ALK inhibitors.

Ophthalmological Effects

Visual disturbance is an AE to crizotinib,11 although rare cases of blurred vision have been reported with ceritinib27 and alectinib.33 Events usually happen early (median time to onset <2 weeks), are generally short lived, are not associated with clinically meaningful changes at ophthalmological assessment and have a minimal impact on activities of daily living.38 Patients are advised to refrain from driving or operating machinery if they experience visual disturbance.11 If these events worsen in severity, ophthalmic assessment should be considered. Rare cases of optic neuropathy and blindness have been reported following administration of crizotinib,39 and this AE warrants further investigation.

Blood Glucose Effects

Hyperglycaemia may occur in patients taking ceritinib. It is therefore important to monitor serum glucose levels and initiate or optimise anti-hyperglycaemic medications as needed. If the drug effect is severe (persistent hyperglycaemia >250 mg/dl despite optimal antihyperglycaemic therapy), ceritinib should be discontinued until glycemic control is achieved, then resumed with a 150 mg dose reduction If adequate hyperglycaemic control cannot be achieved with optimal medical management, ceritinib should be discontinued.27

Other Effects

Hypophosphataemia has been reported in a small proportion of patients taking ALK inhibitors. In severe cases, parenteral phosphate may be used but this is much more dangerous and requires monitoring of calcium, phosphate and electrolyte levels every 6 hours as response is unpredictable, and should only be used when serum phosphate levels are under 1.5 mmol/l.40

Hypogonadism is a frequent and undiagnosed occurrence in advanced cancer patients,41 and can be particularly distressing for NSCLC patients who may be relatively young and likely to be on therapy for a long time. Symptoms of androgen deficiency and reduced testosterone levels have been reported in patients taking crizotinib: in a study of 32 crizotinibtreated and 19 non-crizotinib treated patients, mean total testosterone levels were 25 % below the lower limit of normal (LLN) in 84 % of crizotinib-treated patients compared with 29 % above LLN in 32 % of the non-crizotinib-treated patients; p=0.0012. Five of nine patients (55 %) with low testosterone were given testosterone supplementation and subsequently showed in symptoms, together with increases in testosterone above LLN..42 It is therefore advisable to monitor testosterone levels at baseline and at regular intervals in male patients.11

Peripheral oedema has been reported in patients taking crizotinib (grade 1–2, up to a third of patients)23–25 and alectinib (15 % grade 1–2; 2 % grade 3).17 No specific recommendations have been made for management of this AE, but conservative management strategies, such as leg elevation, compression stockings and dietary salt modification, may be considered.32

ALK Inhibitors During Pregnancy

There are no adequate and well-controlled studies in pregnant women using ALK inhibitors; however, non-clinical studies indicate that these agents may cause foetal harm when administered to pregnant women and crizotinib and ceritinib have been placed in FDA pregnancy category D.11,27 It is also advised to avoid pregnancy while taking alectinib.35 Breastfeeding is not recommended during use of these agents.

Drug Interactions

Crizotinib, ceritinib and alectinib are metabolised primarily by CYP3A4.11,27 Concurrent use of these agents with strong CYP3A inhibitors and strong CYP3A inducers should be avoided. If concurrent use of a strong CYP3A inhibitor is unavoidable, crizotinib and ceritinib should be reduced by one-third. Patients should avoid grapefruit and grapefruit juice as these are strong CYP3A4 inhibitors.27

Patient and Physician Education
The key to successful management of patients taking ALK inhibitors is careful patient selection before drug administration, followed by education of both physician and patient. The prescribing physician should be familiar with the package insert contents.33 Finally, regular patient surveillance, in terms of blood tests and concomitant drug use, is essential.

Summary and Concluding Remarks
ALK inhibitors represent a new treatment paradigm in NSCLC, offering improved outcomes compared with cytotoxic chemotherapy.

However, these agents target multiple pathways and are therefore associated with a wide range of AEs, including gastrointestinal AEs, and hepatotoxicity. While the majority of AEs are reversible, manageable and not severe, it is important that both physician and patients are aware of toxicities to ensure prompt treatment. There is a need for proactive treatment of the first symptoms to prevent more severe AEs. There is also a need for further studies to fully elucidate the differences in AE profiles between different ALK inhibitors, including long-term studies. While newer ALK inhibitors are associated with fewer AES, crizotinib, ceritinib and alectinib all represent valuable therapeutic options. Management of AEs will improve the therapeutic index of these agents and enhance quality of life for patients.

Article Information:
Disclosure

Christian Rolfo has served on the Novartis International Speakers Bureau. Solange Peters and Ignacio Gil-Bazo have no conflicts of interest to declare.

Correspondence

Christian Rolfo, Associate Professor, University Hospital Antwerp Oncology, Head of Phase I Early Clinical Trials Unit, Antwerp, Belgium.
E: Christian.Rolfo@uza.be

Support

The publication of this article was supported by Novartis, who were given the opportunity to review the article for scientific accuracy before submission. Any resulting changes were made at the author’s discretion.

Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.

Received

2015-05-12T00:00:00

References

1. Love N, Anderson, KC, Flaherty K, et al., Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents, J Clin Oncol, 2013;31(Suppl. abstract e17570).
2. Salgia R, Skarin AT, Molecular abnormalities in lung cancer, J Clin Oncol, 1998;16:1207–17.
3. Markovic J, Stojsic J, Zunic S, et al., Genomic instability in patients with non-small cell lung cancer assessed by the arbitrarily primed polymerase chain reaction, Cancer Invest, 2008;26:262–8.
4. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 2007;448:561–6.
5. Soda M, Takada S, Takeuchi K, et al., A mouse model for EML4-ALK-positive lung cancer, Proc Natl Acad Sci U S A, 2008;105:19893–7.
6. Shaw AT, Engelman JA, ALK in lung cancer: past, present, and future, J Clin Oncol, 2013;31:1105–11.
7. Shaw AT, Yeap BY, Mino-Kenudson M, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 2009;27:4247–53.
8. Subramanian J, Govindan R, Lung cancer in never smokers: a review, J Clin Oncol, 2007;25:561–70.
9. Shaw AT, Solomon B, Targeting anaplastic lymphoma kinase in lung cancer, Clin Cancer Res, 2011;17:2081–6.
10. Ou SH, Kwak EL, Siwak-Tapp C, et al., Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a nonsmall cell lung cancer patient with de novo MET amplification, J Thorac Oncol, 2011;6:942–6.
11. Pfizer, Xalkori [crizotinib, package insert]; Highlights of prescribing information. Available at: https://www.accessdata. fda.gov/drugsatfda_docs/label/2012/202570s002lbl.pdf (accessed 20 October 2014).
12. Katayama R, Shaw AT, Khan TM, et al., Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 2012;4:120ra17.
13. Doebele RC, Pilling AB, Aisner DL, et al., Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 2012;18:1472–82.
14. Marsilje TH, Pei W, Chen B, et al., Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials, J Med Chem, 2013;56:5675–90.
15. Dhillon S, Clark M, Ceritinib: first global approval, Drugs, 2014;74:1285–91.
16. Shaw AT, Kim DW, Mehra R, et al., Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 2014;370:1189–97.
17. Gadgeel SM, Gandhi L, Riely GJ, et al., Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-smallcell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol, 2014;15:1119–28.
18. Gettinger SN, Bazhenova L, Salgia R, et al., Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC), J Clin Oncol, 32:5s, 2014;32:5s (Suppl. abstr 8047).
19. Lovly CM, Heuckmann JM, de Stanchina E, et al., Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors, Cancer Res, 2011;71:4920–31.
20. Zou HY, Engstrom LR, Li Q, Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo, Mol Cancer Ther, 2013;12:Abstr C253.
21. Mori M, Ueno Y, Konagai S, et al., The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice, Mol Cancer Ther, 2014;13:329–40.
22. Weiss GJ, Sachdev JC, Infante JR, et al., Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations, J Clin Oncol, 2014;32(Suppl. abstr e19005).
23. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 2013;368:2385–94.
24. Solomon BJ, Mok T, Kim DW, et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 2014;371:2167–77.
25. Camidge DR, Bang YJ, Kwak EL, et al., Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 2012;13:1011–9.
26. Kim D-W, Mehra R, Tan D S-W, et al., Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) nonsmall cell lung cancer (NSCLC): Results of the ASCEND-1 trial, J Clin Oncol, 2014;32:5s (Suppl. abstr 8003).
27. Novartis, Zykadia; Highlights of Prescribing information. Available at: https://www.pharma.us.novartis.com/product/pi/ pdf/zykadia.pdf (accessed 16 October 2014).
28. Nakagawa K, Hida T, Seto T, et al., Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study, J Clin Oncol, 2014;32:Suppl. abtr 8103.
29. Seto T, Kiura K, Nishio M, et al., CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study, Lancet Oncol, 2013;14:590–8.
30. Ou S-HI, Ahan JS, De Petris L, et al., Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673), J Clin Oncol, 2015;33(Suppl. abstr 8008).
31. Gandhi L, Shaw A, Gadgeel SM, et al., A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761), J Clin Oncol, 2015;33(Suppl. abstr 8019).
32. Rothenstein JM, Letarte N, Managing treatment-related adverse events associated with Alk inhibitors, Curr Oncol, 2014;21:19–26.
33. Information Meeting on ALECENSA®. Available at: https://www. chugai-pharm.co.jp/html/meeting/pdf/140821eAlecensa.pdf (accessed 3 February 2015).
34. Koizumi T, Fukushima T, Tatai T, et al., Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer, Lung Cancer, 2015;88:112–3.
35. Alecensa, Drug Information Sheet (“Kusuri-no-Shiori”). Available at: https://chugai-pharm.jp/hc/ss/pr/drug/alc_ cap00040/shiori/PDF/en/alc_s_en.pdf (accessed 3 February 2015).
36. Pfizer, Highlights of prescribing information. Available at: https://labeling.pfizer.com/showlabeling.aspx?id=676 (accessed 3 February 2015).
37. Yanagisawa S, Inoue A, Koarai A, et al., Successful crizotinib retreatment after crizotinib-induced interstitial lung disease, J Thorac Oncol, 2013;8:e73–4.
38. Salgia R, Soloman BJ, Shaw AT, et al., Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC) patients treated with crizotinib, J Clin Oncol, 2012;30(Suppl):abstr 7596.
39. Chun SG, Iyengar P, Gerber DE, et al., Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation, J Clin Oncol, 2015;33:e25–6.
40. Imel EA, Econs MJ, Approach to the hypophosphatemic patient, J Clin Endocrinol Metab, 2012;97:696–706.
41. Vigano A, Piccioni M, Trutschnigg B, et al., Male hypogonadism associated with advanced cancer: a systematic review, Lancet Oncol, 2010;11:679–84.
42. Weickhardt AJ, Doebele RC, Purcell WT, et al., Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients, Cancer, 2013;119:2383–90.
43. Sakamoto H, Tsukaguchi T, Hiroshima S, et al., CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant, Cancer Cell, 2011;19:679–90.

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72